KRISHNA INST OF MED SCI L Latest Share Price (KIMS)
TODAY IN ONE LINE
KIMS rose 2.3% on above-average volume (1.7x avg), outperforming Nifty's 0.3% move, supported by recent strong earnings.
With a market cap of ₹34,020.53 Cr., it trades at a P/E of 160.08. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
KRISHNA INST OF MED SCI L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 25.4%
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 58.3% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 137.7x
- ●Promoter SellingPromoter holding decreased by 1.61% QoQ
- ●Rising Receivables vs SalesReceivables grew 47.4% outpacing sales growth of 21.5%
Latest KRISHNA INST OF MED SCI L News
What changed recently?
Recent events, corporate actions, and announcements.
KRISHNA INST OF MED SCI L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for KRISHNA INST OF MED SCI L, framed against the sector median so the premium or discount is obvious at a glance.
KRISHNA INST OF MED SCI L trades at a P/E of 160.08× and P/B of 14.42×, against the Healthcare sector median P/E of 45.85×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
KRISHNA INST OF MED SCI L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for KRISHNA INST OF MED SCI L — derived from the latest tape, not yesterday's close.
KRISHNA INST OF MED SCI L last traded at ₹809.85 with an intraday range of ₹784–₹819 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹809.85| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 894.57 | +84.72 | +10.46% |
| R3 | 859.57 | +49.72 | +6.14% |
| R2 | 839.28 | +29.43 | +3.63% |
| R1 | 824.57 | +14.72 | +1.82% |
| PIVOT | 804.28 | -5.57 | -0.69% |
| CURRENT | 809.85 | — | — |
| S1 | 789.57 | -20.28 | -2.50% |
| S2 | 769.28 | -40.57 | -5.01% |
| S3 | 754.57 | -55.28 | -6.83% |
| S4 | 719.57 | -90.28 | -11.15% |
KIMS is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹784–₹796
Trading Above opening range, showing Bullishness
KRISHNA INST OF MED SCI L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for KRISHNA INST OF MED SCI L — consolidated or standalone — with margins, YoY growth and key ratios inline.
KRISHNA INST OF MED SCI L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹34,020.53 Cr. and reported EPS of ₹0.99.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 3,035 | 3,905 ▲ 28.6% |
| Sales Growth YoY %Derived | 21.49% | 28.65% |
| Other Income | 32 | 26 ▼ 17.9% |
| Total Income | 3,067 | 3,931 ▲ 28.2% |
| 627 | 809 ▲ 29.0% | |
| Gross ProfitDerived | 2,408 | 3,096 ▲ 28.5% |
| Gross Margin %Derived | 79.34% | 79.28% |
| 1,625 | 2,294 ▲ 41.1% | |
| EBITDA (Operating Profit)Derived | 783 | 802 ▲ 2.4% |
| OPM %Derived | 25.79% | 20.54% |
| 278 | 475 ▲ 70.5% | |
| Profit Before Tax (PBT) | 558 | 331 ▼ 40.6% |
| 143 | 92 ▼ 35.9% | |
| Effective Tax %Derived | 25.68% | 27.74% |
| Total Profit for Period | 415 | 242 ▼ 41.7% |
| Less: Non-controlling Interests | 30 | 1 ▼ 98.0% |
| Net Profit (Owner's PAT)Derived | 385 | 241 ▼ 37.2% |
| Net Profit Margin %Derived | 12.67% | 6.18% |
| PAT Growth YoY %Derived | 23.97% | -37.22% |
| Earnings Per Share (EPS ₹) | 9.61 | 6.03 ▼ 37.3% |
| Diluted Shares Outstanding (Cr) | 40 | 40 ▲ 0.0% |
| Share of Profit from Associates/JVs | — | 3 |
| Other Comprehensive Income (Net of Tax) | -2 | 0 ▲ 108.7% |
| Total Expenses (incl. D&A & Interest) | 2,509 | 3,600 ▲ 43.5% |
| Material Cost % of RevenueDerived | — | — |
| Employee Cost % of RevenueDerived | 16.46% | 17.46% |
| Other Cost % of RevenueDerived | 37.09% | 41.28% |
| Interest Coverage (x)Derived | 6.71x | 2.56x |
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,330 | 1,651 ▲ 24.1% | 2,198 ▲ 33.1% | 2,498 ▲ 13.7% | 3,035 ▲ 21.5% | 3,905 ▲ 28.6% | |
| Sales Growth YoY %Derived | — | 24.13% | 33.13% | 13.67% | 21.49% | 28.65% | |
| Other Income | 10 | 20 ▲ 99.3% | 26 ▲ 27.7% | 13 ▼ 49.5% | 32 ▲ 144.3% | 26 ▼ 17.9% | |
| Total Income | 1,340 | 1,671 ▲ 24.7% | 2,224 ▲ 33.1% | 2,511 ▲ 12.9% | 3,067 ▲ 22.1% | 3,931 ▲ 28.2% | |
289 | 355 ▲ 22.9% | 481 ▲ 35.3% | 530 ▲ 10.3% | 627 ▲ 18.2% | 809 ▲ 29.0% | ||
| Gross ProfitDerived | 1,041 | 1,296 ▲ 24.5% | 1,717 ▲ 32.5% | 1,968 ▲ 14.6% | 2,408 ▲ 22.4% | 3,096 ▲ 28.5% | |
| Gross Margin %Derived | 78.27% | 78.49% | 78.13% | 78.77% | 79.34% | 79.28% | |
670 | 780 ▲ 16.4% | 1,113 ▲ 42.7% | 1,327 ▲ 19.3% | 1,625 ▲ 22.4% | 2,294 ▲ 41.1% | ||
| EBITDA (Operating Profit)Derived | 371 | 516 ▲ 39.1% | 604 ▲ 17.1% | 640 ▲ 6.0% | 783 ▲ 22.2% | 802 ▲ 2.4% | |
| OPM %Derived | 27.89% | 31.24% | 27.48% | 25.64% | 25.79% | 20.54% | |
102 | 89 ▼ 13.1% | 175 ▲ 96.9% | 194 ▲ 10.8% | 278 ▲ 43.8% | 475 ▲ 70.5% | ||
| Profit Before Tax (PBT) | 279 | 447 ▲ 60.3% | 485 ▲ 8.4% | 460 ▼ 5.2% | 558 ▲ 21.4% | 331 ▼ 40.6% | |
74 | 114 ▲ 55.5% | 119 ▲ 4.2% | 124 ▲ 3.8% | 143 ▲ 15.9% | 92 ▼ 35.9% | ||
| Effective Tax %Derived | 26.36% | 25.56% | 24.56% | 26.88% | 25.68% | 27.74% | |
| Total Profit for Period | 205 | 344 ▲ 67.3% | 366 ▲ 6.4% | 336 ▼ 8.1% | 415 ▲ 23.4% | 242 ▼ 41.7% | |
| Less: Non-controlling Interests | 4 | 11 ▲ 160.8% | 29 ▲ 165.4% | 26 ▼ 12.3% | 30 ▲ 17.2% | 1 ▼ 98.0% | |
| Net Profit (Owner's PAT)Derived | 201 | 333 ▲ 65.3% | 336 ▲ 1.1% | 310 ▼ 7.8% | 385 ▲ 24.0% | 241 ▼ 37.2% | |
| Net Profit Margin %Derived | 15.13% | 20.15% | 15.30% | 12.42% | 12.67% | 6.18% | |
| PAT Growth YoY %Derived | — | 65.33% | 1.09% | -7.78% | 23.97% | -37.22% | |
| Earnings Per Share (EPS ₹) | 5.03 | 8.31 ▲ 65.2% | 8.41 ▲ 1.2% | 7.75 ▼ 7.8% | 9.61 ▲ 24.0% | 6.03 ▼ 37.3% | |
| Diluted Shares Outstanding (Cr) | 40 | 40 ▲ 0.0% | 40 ▲ 0.0% | 40 ▲ 0.0% | 40 ▲ 0.0% | 40 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | 10 | — ▼ 100.0% | -0 | — ▲ 100.0% | 3 | |
| Other Comprehensive Income (Net of Tax) | -0 | 0 ▲ 125.9% | 1 ▲ 609.2% | 0 ▼ 61.7% | -2 ▼ 805.5% | 0 ▲ 108.7% | |
| Total Expenses (incl. D&A & Interest) | 1,061 | 1,224 ▲ 15.3% | 1,739 ▲ 42.1% | 2,051 ▲ 18.0% | 2,509 ▲ 22.3% | 3,600 ▲ 43.5% | |
| Material Cost % of RevenueDerived | 21.25% | — | — | — | — | — | |
| Employee Cost % of RevenueDerived | 16.56% | 15.87% | 15.76% | 16.91% | 16.46% | 17.46% | |
| Other Cost % of RevenueDerived | 33.83% | 31.38% | 34.88% | 36.23% | 37.09% | 41.28% | |
| Interest Coverage (x)Derived | 9.27x | 27.64x | 15.54x | 10.50x | 6.71x | 2.56x |
KRISHNA INST OF MED SCI L segment analysis : revenue and profit mix.
Disclosed business segments at KRISHNA INST OF MED SCI L with their share of revenue and profit, switchable between consolidated and standalone reporting.
KRISHNA INST OF MED SCI L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for KRISHNA INST OF MED SCI L.
Our AI distills the core fundamental drivers supporting KRISHNA INST OF MED SCI L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
KRISHNA INST OF MED SCI L's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 208 (~4.5× the sector multiple of 45.9) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.10. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
KRISHNA INST OF MED SCI L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — KRISHNA INST OF MED SCI L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
KRISHNA INST OF MED SCI L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for KRISHNA INST OF MED SCI L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
KRISHNA INST OF MED SCI L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for KRISHNA INST OF MED SCI L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in KRISHNA INST OF MED SCI L stood at 61.2% of traded volume, against a 20-day average of 62.6%.
KRISHNA INST OF MED SCI L announcements: results, concalls, ratings, M&A.
Filings KRISHNA INST OF MED SCI L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
KRISHNA INST OF MED SCI L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 171 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Krishna Institute of Medical Sciences Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Krishna Institute of Medical Sciences Limited has informed the Exchange about Schedule of meet
Agreements
Krishna Institute of Medical Sciences Limited has informed the Exchange about entering into an Operations and Management Agreement with Sarvottam…
Analysts/Institutional Investor Meet/Con. Call Updates
Krishna Institute of Medical Sciences Limited has informed the Exchange about Schedule of meet
Shareholders meeting
Krishna Institute of Medical Sciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 27,…
Investor decks & rating reports.
KRISHNA INST OF MED SCI L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue KRISHNA INST OF MED SCI L has declared, sequenced by announce and record date.
KRISHNA INST OF MED SCI L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About KRISHNA INST OF MED SCI L: business, sector, key facts.
What KRISHNA INST OF MED SCI L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
KRISHNA INST OF MED SCI L operates in the Hospital industry under the Healthcare sector, listed as NSE: KIMS, BSE: 543308.
KIMS Hospitals, officially Krishna Institute of Medical Sciences Limited, is a prominent healthcare provider in India, operating under the KIMS Hospitals brand. Their business centers on delivering a comprehensive range of medical and healthcare services across numerous specialties. This wide-ranging approach allows them to cater to a diverse patient population with varied healthcare needs.
The company's service offerings span a broad spectrum of medical disciplines. Key specialties include cardiology, neurology, oncology, orthopedics, nephrology, reproductive medicine, and robotic surgery. Beyond these core areas, KIMS also provides services in gastroenterology and hepatology, heart and lung transplants, other organ transplantation procedures, mother and childcare, and pediatrics. This comprehensive approach ensures a wide array of patient needs can be addressed within their facilities.
Further specializing their services, KIMS focuses on areas such as accident and emergency care, biochemistry, anesthesiology, bariatric surgery, andrology and infertility treatments, arthroscopy, and Alzheimer's disease management. They also possess expertise in various specialized centers, including bone and joint centers. This detailed specialization allows for targeted expertise and advanced treatment options in specific medical fields.
The breadth of their procedural capabilities is equally impressive. KIMS performs a wide variety of medical procedures, including those related to aneurysms, ankle arthritis and replacements, cervical discectomies and fusions, anterior resections, aortic aneurysms and stent grafts, aortic valve replacements, arthroscopies, atrial septal defects, and bariatric surgeries. This extensive procedural capacity demonstrates a high level of technological and surgical proficiency.
Established in 1973 and headquartered in Secunderabad, India, KIMS Hospitals has a long history of providing healthcare services within the country. Their continued growth and expansion into diverse medical specialties highlights their commitment to providing advanced and comprehensive healthcare solutions to the Indian population.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- DR AGARWALS HEALTH CARE L (AGARWALEYE) Share PricePeer
- APOLLO HOSPITALS ENTER L (APOLLOHOSP) Share PricePeer
- ARTEMIS MED SERVICE (ARTEMISMED) Share PricePeer
- ASTER DM QUALITY CARE (ASTERDM) Share PricePeer
- FORTIS HEALTHCARE (FORTIS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about KRISHNA INST OF MED SCI L (KIMS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of KRISHNA INST OF MED SCI L (KIMS)?
The current share price of KRISHNA INST OF MED SCI L (KIMS) is ₹809.85. Today, the stock has gained by ₹18.00 (2.27%), trading in a range of ₹784.00 to ₹819.00. The stock opened at ₹793.40 with a trading volume of 12,42,321 shares.
02Is KRISHNA INST OF MED SCI L stock a good investment for long-term?
KRISHNA INST OF MED SCI L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹34,020.53 Cr., P/E ratio of 160.08, ROE of 10.73%, and ROCE of 8.27%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of KRISHNA INST OF MED SCI L stock?
The 52-week high price of KRISHNA INST OF MED SCI L (KIMS) is ₹858.00, while the 52-week low is ₹575.80. Currently trading at ₹809.85, the stock is 40.65% above its 52-week low and 5.61% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy KRISHNA INST OF MED SCI L stock at the current price?
Whether to buy KRISHNA INST OF MED SCI L stock at ₹809.85 depends on multiple factors. The stock is currently trading with a P/E ratio of 160.08 and P/B ratio of 14.42. Today's performance shows a gain of 2.27%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of KRISHNA INST OF MED SCI L and when is the next dividend?
KRISHNA INST OF MED SCI L offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹809.85, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of KRISHNA INST OF MED SCI L?
KRISHNA INST OF MED SCI L's key financial metrics include: P/E Ratio: 160.08, P/B Ratio: 14.42, ROE: 10.73%, ROCE: 8.27%, Dividend Yield: 0%, EPS: ₹0.99, Book Value: ₹60.92, and Debt-to-Equity: 0.6. The company's market cap stands at ₹34,020.53 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is KRISHNA INST OF MED SCI L stock performing today in the market?
KRISHNA INST OF MED SCI L stock opened at ₹793.40 and is currently trading at ₹809.85, showing a gain of ₹18.00 (2.27%). The intraday high is ₹819.00 and low is ₹784.00. The trading volume stands at 12,42,321 shares, indicating strong market participation today.
08What is the P/E ratio of KRISHNA INST OF MED SCI L and what does it indicate?
KRISHNA INST OF MED SCI L has a Price-to-Earnings (P/E) ratio of 160.08, which means investors are willing to pay 160.08 for every ₹1 of earnings. With an EPS of ₹0.99, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about KRISHNA INST OF MED SCI L (KIMS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.